Cargando…

Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway

BACKGROUND: Death by suicide in patients enrolled in opioid agonist therapy (OAT) is a major clinical concern. However, little knowledge exists regarding suicide attempts in this patient group. This study presents the lifetime prevalence of suicide attempts and the associations between suicide attem...

Descripción completa

Detalles Bibliográficos
Autores principales: Vold, Jørn Henrik, Løberg, Else-Marie, Aas, Christer F., Steier, Jan Alexander, Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922793/
https://www.ncbi.nlm.nih.gov/pubmed/35291968
http://dx.doi.org/10.1186/s12888-022-03829-y
_version_ 1784669566078550016
author Vold, Jørn Henrik
Løberg, Else-Marie
Aas, Christer F.
Steier, Jan Alexander
Johansson, Kjell Arne
Fadnes, Lars Thore
author_facet Vold, Jørn Henrik
Løberg, Else-Marie
Aas, Christer F.
Steier, Jan Alexander
Johansson, Kjell Arne
Fadnes, Lars Thore
author_sort Vold, Jørn Henrik
collection PubMed
description BACKGROUND: Death by suicide in patients enrolled in opioid agonist therapy (OAT) is a major clinical concern. However, little knowledge exists regarding suicide attempts in this patient group. This study presents the lifetime prevalence of suicide attempts and the associations between suicide attempts and clinical and sociodemographic variables such as education, sex, early onset of substance use (< 13 years of age), substance use patterns, and injecting substance use among patients receiving OAT. METHODS: We used data from a cohort of OAT patients in Norway obtained from a health assessment of self-reported suicide attempts and sociodemographic and clinical factors. A total of 595 patients receiving OAT were assessed from 2016 to 2020. A binary logistic regression analysis was performed and reported with an unadjusted odds ratio and 95% confidence intervals (OR). The purpose of this assessment was to analyze associations between suicide attempts and substance use patterns as well as the injection of substances during the 30 days leading up to the health assessment. A negative binomial regression analysis with an incidence rate ratio and 95% confidence intervals (IRR) was performed to investigate sex, education, early onset of substance use, and the number of suicide attempts. RESULTS: Forty-one percent of the OAT patients had attempted to die by suicide at least once during their lifetime. An early onset of substance use was strongly associated with the suicide attempts (IRR: 1.7, 1.3–2.2). No significant association was found between suicide attempts and sex (IRR: 1.2, 0.9–1.6) or education (IRR: 0.6, 0.2–2.1). Likewise, no association was identified between suicide attempts and injecting substance use (OR: 0.9, 0.6–1.3), nor using alcohol (OR: 0.9, 0.7–1.3), amphetamines (OR: 1.0, 0.7–1.3), benzodiazepines (OR: 1.0, 0.7–1.4), cannabis (OR: 1.2, 0.9–1.7), cocaine (OR: 1.3, 0.6–3.0), or opioids (OR: 1.4, 0.9–2.0). CONCLUSION: The lifetime prevalence of suicide attempts was alarmingly high in the OAT population. An early onset of substance use seemed to be an important risk factor for suicide attempts. There was a non-significant association to more current use of opioids among OAT patients with previous suicide attempts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-03829-y.
format Online
Article
Text
id pubmed-8922793
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89227932022-03-22 Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway Vold, Jørn Henrik Løberg, Else-Marie Aas, Christer F. Steier, Jan Alexander Johansson, Kjell Arne Fadnes, Lars Thore BMC Psychiatry Research BACKGROUND: Death by suicide in patients enrolled in opioid agonist therapy (OAT) is a major clinical concern. However, little knowledge exists regarding suicide attempts in this patient group. This study presents the lifetime prevalence of suicide attempts and the associations between suicide attempts and clinical and sociodemographic variables such as education, sex, early onset of substance use (< 13 years of age), substance use patterns, and injecting substance use among patients receiving OAT. METHODS: We used data from a cohort of OAT patients in Norway obtained from a health assessment of self-reported suicide attempts and sociodemographic and clinical factors. A total of 595 patients receiving OAT were assessed from 2016 to 2020. A binary logistic regression analysis was performed and reported with an unadjusted odds ratio and 95% confidence intervals (OR). The purpose of this assessment was to analyze associations between suicide attempts and substance use patterns as well as the injection of substances during the 30 days leading up to the health assessment. A negative binomial regression analysis with an incidence rate ratio and 95% confidence intervals (IRR) was performed to investigate sex, education, early onset of substance use, and the number of suicide attempts. RESULTS: Forty-one percent of the OAT patients had attempted to die by suicide at least once during their lifetime. An early onset of substance use was strongly associated with the suicide attempts (IRR: 1.7, 1.3–2.2). No significant association was found between suicide attempts and sex (IRR: 1.2, 0.9–1.6) or education (IRR: 0.6, 0.2–2.1). Likewise, no association was identified between suicide attempts and injecting substance use (OR: 0.9, 0.6–1.3), nor using alcohol (OR: 0.9, 0.7–1.3), amphetamines (OR: 1.0, 0.7–1.3), benzodiazepines (OR: 1.0, 0.7–1.4), cannabis (OR: 1.2, 0.9–1.7), cocaine (OR: 1.3, 0.6–3.0), or opioids (OR: 1.4, 0.9–2.0). CONCLUSION: The lifetime prevalence of suicide attempts was alarmingly high in the OAT population. An early onset of substance use seemed to be an important risk factor for suicide attempts. There was a non-significant association to more current use of opioids among OAT patients with previous suicide attempts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-03829-y. BioMed Central 2022-03-15 /pmc/articles/PMC8922793/ /pubmed/35291968 http://dx.doi.org/10.1186/s12888-022-03829-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vold, Jørn Henrik
Løberg, Else-Marie
Aas, Christer F.
Steier, Jan Alexander
Johansson, Kjell Arne
Fadnes, Lars Thore
Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title_full Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title_fullStr Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title_full_unstemmed Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title_short Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
title_sort prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in norway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922793/
https://www.ncbi.nlm.nih.gov/pubmed/35291968
http://dx.doi.org/10.1186/s12888-022-03829-y
work_keys_str_mv AT voldjørnhenrik prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway
AT løbergelsemarie prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway
AT aaschristerf prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway
AT steierjanalexander prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway
AT johanssonkjellarne prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway
AT fadneslarsthore prevalenceandcorrelatesofsuicideattemptsinhighriskpopulationsacrosssectionalstudyamongpatientsreceivingopioidagonisttherapyinnorway